15 Apr Saizen instructions for use, analogues, composition, indications
Saizen: instructions for use, analogues, composition, indications
Saizen – instructions, indications for use, indications and contraindications. Availability in pharmacies, prices and analogues of Saizen on the site 103.by
Treatment with Saizen® should be carried out under the constant supervision of a physician experienced in the diagnosis and treatment of patients with growth hormone deficiency. Patients with intra- and extracranial neoplasms in remission receiving growth hormone therapy should be followed up by a doctor at regular intervals.
Patients with growth hormone deficiency as a result of intracranial neoplasm, receiving therapy with Saizen®, should be regularly examined for progression or recurrence of the underlying disease
Saizen® is not intended for the long-term treatment of pediatric patients with growth retardation as a result of confirmed Prader-Willi syndrome, even in the presence of confirmed growth hormone deficiency. Fatal cases of respiratory arrest during sleep have been reported following initiation of growth hormone therapy in pediatric patients with Prader-Willi syndrome and the following risk factors: severe obesity, history of upper airway obstruction or “sleep apnea”, unidentified respiratory infections Leukemia
Cases of leukemia have been reported in some patients with growth hormone deficiency, some of whom received somatropin therapy. However, to date, there is no evidence of a relationship between the risk of leukemia and the use of growth hormone.
Since somatropin reduces the sensitivity of the insulin receptors, patients should be monitored regularly for impaired glucose tolerance. In persons with diabetes mellitus or with a family history of diabetes mellitus, the drug should be administered with caution. Patients with diabetes mellitus may need to adjust the insulin dose after starting growth hormone therapy.
Stable retinopathy should not be a reason for discontinuing somatropin therapy. In the event of preproliferative changes or the presence of proliferative retinopathy, growth hormone therapy should be discontinued.
The use of growth hormone increases the extra-thyroid conversion of T4 to TK. And can boldenone undecylenate for sale, in particular, to unmask hypothyroidism. Thyroid function should be monitored in all patients. Thyroid function should be assessed before starting therapy and monitored regularly during treatment. In patients with impaired pituitary function, standard replacement therapy should be tightly controlled against the background of ongoing growth hormone therapy.
Benign intracranial hypertension
In the event of severe or persistent headaches, blurred vision, nausea and / or vomiting, a fundoscopy should be performed to detect swelling of the optic papilla. The study of the fundus should be carried out before starting Saizen therapy (to exclude the existing edema of the optic nerve nipple) and be repeated later in case of suspicion of the development of this pathology. In case of edema of the optic nerve papilla, treatment with somatropin should be discontinued. Treatment may be resumed at lower doses after benign intracranial hypertension (which usually resolves quickly after discontinuation of the drug). In this case, the patient should be monitored for symptoms of benign intracranial hypertension, in case of recurrence of this complication, treatment should be discontinued.
A small percentage of patients who received somatropin-containing products showed the appearance of antibodies to somatropin. The binding capacity of this type of antibodies was low and did not affect the growth rate. Despite this, all patients with no effect from the use of growth hormone should be examined for antibodies..
Epiphysiolysis of the femoral head is often associated with endocrine disorders such as growth hormone deficiency and pshothyroidism. In children treated with growth hormone, femoral head epiphysiolysis may result from both endocrine disruption and an increase in skeletal growth. The dramatic increase in growth rates can be the cause of joint problems. The attending physician and parents should not lose sight of this fact and be alert when a child complains of pain in the hip and / or knee joints during treatment with Saizen®.
Patients with stunting due to chronic renal failure should be regularly evaluated for progression of renal osteodystrophy. Epiphysiolysis of the femoral head or aseptic necrosis of the femoral head can occur in children with severe renal osteodystrophy. At present, the connection between the occurrence of these complications and growth hormone therapy has not been finally established. X-rays of the hip joints should be performed in such patients prior to initiation of therapy..
In children with chronic renal failure, renal function should be reduced by 50% or more before starting therapy. To verify growth abnormalities, the growth rate should be monitored for 1 year before starting treatment. Conservative treatment of renal failure should be carried out for 1 year before starting therapy and maintained throughout the entire period of treatment. Therapy should be suspended for the duration of the kidney transplant.
In children diagnosed with growth retardation due to intrauterine growth retardation, other causes of growth retardation should be ruled out before starting treatment.
In children diagnosed with growth retardation as a result of intrauterine growth retardation, before starting treatment, the level of insulin and glucose in the blood serum should be determined on an empty stomach and these studies should be carried out annually. In the presence of diabetes mellitus, Saizen® treatment is not recommended.
In children with a diagnosis of growth retardation as a result of intrauterine growth retardation, it is recommended to determine the level of insulin-like growth factor before starting treatment and then twice a year. If the level of the insulin-like factor of the robot reaches +2 standard deviations in comparison!
indicators and adolescent status, the results of this study should be taken into account when adjusting the dose.
Patient treatment experience how to make synthol with a history of intrauterine growth retardation, subject to initiation of treatment in adolescence is limited. The experience of treating patients with a history of intrauterine growth retardation in combination with Silver-Roussel syndrome is limited.
In adults, during the period of therapy with growth hormone, fluid retention in the body may be observed.
In case of persistent edema and severe paresthesia, the dose should be reduced to avoid the development of carpal tunnel syndrome..
Injection sites should be changed to avoid lipoatrophy..
The final growth of children diagnosed with growth retardation due to intrauterine growth retardation will not be achieved if Saizen® treatment is discontinued before final growth is achieved.
The introduction of the drug in the same place for long-term damage to this skin area. It is important to constantly change the injection site..
Growth hormone should not be used in case of urgent conditions.
Patients over 60 years of age who are undergoing Saizen® therapy for a long period should be closely monitored, since the experience of using Saizen® in elderly patients is insufficient best prohormone for cutting 2014.
Influence on the ability to drive vehicles and work with mechanisms
Saizen® does not affect the ability to drive vehicles and work with mechanisms.